The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•17 April 2026•

1 min read

Adia Nutrition Partners with Atlanta Clinic for Autism Clinical Study

Key Facts

1Adia Nutrition announced a strategic partnership with a leading Atlanta clinic to launch a clinical study on Autism Spectrum Disorder (ASD).

2Adia Labs will serve as the exclusive supplier of regenerative products for the study.

Adia Nutrition (ADIA) has announced a strategic partnership with a prominent Atlanta-based clinic to initiate a clinical study focused on Autism Spectrum Disorder (ASD). Under the agreement, Adia Labs will serve as the exclusive supplier of regenerative medicine products for the duration of the study. This collaboration aims to expand the application of Adia’s regenerative portfolio into the field of neurodevelopmental disorders while validating product efficacy through rigorous clinical testing. The move represents a significant step in the company's growth strategy to penetrate specialized medical markets. While the news is positive for the company's long-term product validation, the broader market impact remains limited as ADIA is a micro-cap stock listed on the OTCQB.